Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors - sprookjes - yvandenbroek - TriplyDB

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

http://www.wikidata.org/entity/Q24676378

about

Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds Tumor angiogenesis: pericytes and maturation are not to be ignored Preadministration of High-Dose Salicylates, Suppressors of NF- B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy Autocrine PDGFR signaling promotes mammary cancer metastasis Antiangiogenesis cocktails - stirred or shaken?Blasts from the past Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Modes of resistance to anti-angiogenic therapy Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex Why are tumour blood vessels abnormal and why is it important to know?The role of pericytes in blood-vessel formation and maintenance Common ground in the transcriptional profiles of wounds and tumors Pericyte-targeting drug delivery and tissue engineering Tumor refractoriness to anti-VEGF therapy Vascular Wall-Resident Multipotent Stem Cells of Mesenchymal Nature within the Process of Vascular Remodeling: Cellular Basis, Clinical Relevance, and Implications for Stem Cell Therapy Profile of nintedanib in the treatment of solid tumors: the evidence to date Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization Type-2 pericytes participate in normal and tumoral angiogenesis Intertwined regulation of angiogenesis and immunity by myeloid cells Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization Targeting angiogenesis in squamous non-small cell lung cancer Anti-angiogenesis and metastasis: a tumour and stromal cell alliance Today and future of age-related macular degeneration Mouse models for studying angiogenesis and lymphangiogenesis in cancer Pericyte dynamics during angiogenesis: new insights from new identities Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies SIBLINGs and SPARC families: their emerging roles in pancreatic cancer P-Rex1 cooperates with PDGFRβ to drive cellular migration in 3D microenvironments Genetic ablation of Bcl-x attenuates invasiveness without affecting apoptosis or tumor growth in a mouse model of pancreatic neuroendocrine cancer Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells Adaptation to antiangiogenic therapy in neurological tumors Engineering of a Biomimetic Pericyte-Covered 3D Microvascular Network Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization Blood vessels as targets in tumor therapy Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma

P2860

Q21146433-C11316E0-25AC-4A76-ACFB-F72751C3C793 Q21296683-2AE7BA03-6130-4B94-8226-1F18B90677AD Q22299231-404F7020-C900-4995-9551-7B1FF38096FA Q24545375-1EE4E1C3-3E0C-48A5-9D78-AA52ABF38471 Q24548357-42AC4C6A-81D2-4699-B09E-462694515EA0 Q24563415-E8920268-2420-42EE-B66E-41BF7AABB86A Q24563464-428D2EB8-675F-4CA7-AE87-3D25B0958159 Q24595357-09804CA4-89A9-411B-AF62-9AE08CEF386E Q24600542-E812CFFF-E5A2-47D4-BD00-4C8F41977696 Q24608005-05BDED0A-87DF-43CA-9850-8EEFAB108BDA Q24608039-5CE4A282-150D-466F-B6CF-616B5996CC56 Q24623888-C47F512A-3580-4648-82E4-9864B5E1F311 Q24652018-646776D3-F3A1-41D1-9500-3C19BD53D460 Q24683881-DA47B866-56EB-4780-8401-D55CB712B27B Q24804704-BE7F8D99-0C0E-4663-9850-311DD0857F9C Q26745598-AD94C8BF-A851-4C0F-832F-AD580CC39987 Q26747678-65D4A360-B6E1-4CC8-A583-82A769A2E54F Q26765919-2BF8FC52-10CE-47BC-8317-A5EEF6BAA4F1 Q26775134-9D723F64-839E-4195-B2FC-3BD73131A53A Q26781833-F37F8540-21C2-4600-B42E-D75FEF2B1164 Q26782015-F96F982E-F1CA-4A99-A169-0532551541E1 Q26830418-B4E893D9-229C-4CC5-BE76-28BFF478D529 Q26852191-2313DD65-83C3-48F4-8453-0169ED758577 Q26861341-685535D9-606F-459A-B49C-C7D0B722A9E3 Q26862741-3FEDF82D-2C7F-4090-9E6C-10458E0CF526 Q26865643-9D8C3CA4-7FAE-4411-B5C2-35F080CF8B2E Q27003898-FFA45CF3-0B0B-453A-A6BE-2934CB7D6F9A Q27008071-60AA6ED8-2FA3-48B0-AA4E-D8829C594FE8 Q27011840-57D532AF-8611-46C2-B6E3-79B6953CABB3 Q27016629-C14DC84E-5499-48C2-AAA2-73B6B0A6831E Q27027759-D623BED3-D594-4106-A96B-F0A9CFC175B7 Q27320507-38BB6C33-3346-4837-A845-4E01A1BDBF98 Q27355520-500AEE59-AF1A-4794-8107-12D5D4A18381 Q27851455-B178756A-23B8-4498-B8B7-F732F5D22F80 Q28067753-5BA604C7-C906-4C31-A098-1AA54D721E3B Q28082908-10F97265-9BEB-4311-88DA-A918B087E2AF Q28546737-457EC04D-8C73-4098-9029-DEE262239E2E Q28589943-054085B0-9E9A-4667-9B34-B8078641B9D9 Q28590737-DC24CC9F-B884-4002-B298-E2B1FA59C22A Q28732327-4CFE12AC-A518-4AD0-BACF-B789505AB008

P2860

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

http://www.wikidata.org/entity/Q24676378

description

2003 nî lūn-bûn

@nan

2003 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Benefits of targeting both per ...... ulature with kinase inhibitors

@ast

Benefits of targeting both per ...... ulature with kinase inhibitors

@en

Benefits of targeting both per ...... ulature with kinase inhibitors

@nl

type

label

Benefits of targeting both per ...... ulature with kinase inhibitors

@ast

Benefits of targeting both per ...... ulature with kinase inhibitors

@en

Benefits of targeting both per ...... ulature with kinase inhibitors

@nl

prefLabel

Benefits of targeting both per ...... ulature with kinase inhibitors

@ast

Benefits of targeting both per ...... ulature with kinase inhibitors

@en

Benefits of targeting both per ...... ulature with kinase inhibitors

@nl

P1433

Q24676378-B73D1956-883C-43ED-B76C-E0B45CC13AA1

P1476

Q24676378-601CAE0E-A5C3-4244-B7DA-91D5E09EE40B

P2093

Q24676378-26C1F8FD-0F84-4B08-923F-594104736A9D

Q24676378-5AAA74A2-E0F5-4CC5-B657-DF4DA612E9F4

Q24676378-62FEEFCA-906E-454A-8970-A83B354C6DA0

Q24676378-9F8A5F00-45F5-44E9-87C7-AF4ACB9A1E6C

Q24676378-BB02B986-FC11-420E-B980-25CE3B40BFF8

P2860

Q24676378-16295F8C-62E8-4F7C-AD8D-F4DB09D3FD39

Q24676378-185255EE-E839-4F18-B924-9D33520CC3BC

Q24676378-22C545E8-17AA-4951-B1D1-CFB2B1576333

Q24676378-33EC2543-0E35-4B48-9913-93BE6163878E

Q24676378-38EDF5B8-BBAC-4FB8-8D04-CE8BBC2A2332

Q24676378-42630978-337A-49DB-B56E-9A5E77053E59

Q24676378-43F6AA05-1A61-44E9-A8F7-DE4D4CEF3143

Q24676378-469AC693-EA1E-4E25-B4C3-28B4F2D68E71

Q24676378-4A6DF35D-AB73-4DCF-8BBC-D28215650745

Q24676378-625F30FA-D7BC-4620-A208-C376F1BFBD95

P304

Q24676378-4266B160-E7FF-451D-A3E5-E8B1E3099CC4

P31

Q24676378-33C3A719-D995-4B32-9FB9-F7026245F637

P3181

Q24676378-DE950F9F-443D-40F2-B81C-F712F97F40D2

P356

Q24676378-11BDE932-B150-4FEC-8672-610686F647AA

Q24676378-EC2A2A75-B1D9-4222-A170-E252EA8FC824

P407

Q24676378-5B578727-055C-4DC4-9250-824BAE506A63

P433

Q24676378-4A7DC34A-395C-4292-ABC0-C0BBD711C493

P478

Q24676378-4BE95E18-C166-44F2-81EE-E6D28B7F54E9

P577

Q24676378-696D04F3-B818-4A65-881C-E8DA0565EE46

P698

Q24676378-CA493D38-EA4E-4877-B7FF-9EA6F6B96455

P921

Q24676378-F4B1D23F-3907-4622-ACAC-EE176E53B203

P932

Q24676378-6A75AF05-1A81-46EF-92EA-72AAECB778F5

P3181

P356

P1433

Journal of Clinical Investigation

P1476

Benefits of targeting both per ...... ulature with kinase inhibitors

@en

P2093

Douglas Hanahan

http://www.w3.org/2001/XMLSchema#string

Emily Bergsland

http://www.w3.org/2001/XMLSchema#string

Gabriele Bergers

http://www.w3.org/2001/XMLSchema#string

Nicole Meyer-Morse

http://www.w3.org/2001/XMLSchema#string

Steven Song

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice

Pericytes in the microvasculature.

P304

1287-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

678938

http://www.w3.org/2001/XMLSchema#string

P356

10.1172/JCI17929

http://www.w3.org/2001/XMLSchema#string

10.1172/JCI200317929

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12727920

http://www.w3.org/2001/XMLSchema#string

P921

P932

154450

http://www.w3.org/2001/XMLSchema#string